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Accepted 13 January 1994 Abstract This pilot study was performed to compare the occurrence of long term motor complications in Parkinson's disease when the introduction of levodopa was delayed by an initial treatment with high doses of bromocriptine alone. The trial was a prospective randomised controlled study comparing 31 previously untreated patients with Parkinson's disease initially given bromocriptine alone to which levodopa was later added (group BID) and 29 other previously untreated patients with Parkinson's disease immediately given levodopa alone (group D). The end point was the occurrence of the first motor complications (wearing off or dyskinesia). Group B/D patients received bromocriptine (52 (SEM 5) mg/day) for 2*7 years, to which levodopa was later added (471 (SEM 46) mg/day). Group D patients received a comparable dose of levodopa alone (569 (SEM 47) mg/day). Both had similar disability scores at the end of the study. Motor complications were fewer and appeared later in group B/D than in group D (56% after 4-9 (SEM 0 5) years of treatment v 90% after [2] [3] [4] [5] [6] [7] (SEM 0.5) years, p < 0.01). Wearing off appeared later (p < 0-01) in group B/D (4.5 . Antiparkinsonian drugs other than bromocriptine and levodopa were not used during the study. Bromocriptine and levodopa (plus dopa decarboxylase inhibitor) were introduced at low dosages (2-5 and 50 mg respectively) in the form of three nearly equal doses per day that were gradually increased over a three to six week period according to the patient's response. Levodopa and bromocriptine were used all through the study at the lowest doses able to induce sufficient functional improvement as judged by the patient and the physician. High doses of bromocriptine were used as the maximum allowed dose was 90 mg/day. Domperidone (60 mg/daily) was used when needed to prevent nausea, vomiting, or orthostatic hypotension. In group B/D, levodopa was added to bromocriptine when a decline in efficacy of the maximal tolerated dose of bromocriptine occurred or when bromocriptine-induced side effects necessitated lowering the dose, with consequent motor deterioration. Any change in any drug dose was fully documented. There were no significant differences between the two groups. Most patients were at clinical stages I or II when they entered the study.
Patients entered the study from 1982 to 1989. Each of the 60 patients was seen regularly twice a year by the same physician (one of the four authors) throughout the study. 
Results
All the patients included were taken into account, except five in the group B/D. In this group, four patients were still on bromocriptine alone and did not require levodopa adjunction on the last follow up visit (October 1992). None of them presented motor complications. The fifth patient had severe hallucinations after six months of bromocriptine alone (50 mg/day). She was then treated with levodopa alone (600 mg/day) and developed the same complication within three months. She refused to come back to the following visit. She was the only patient lost in the study.
The number of patients reaching the end point when the study terminated was significantly different between the two groups ( similar in both groups (n = 10). We did not find unpredictable on-off phenomena, biphasic dyskinesias, or freezing when walking as first motor complications in this study. Table 2 also shows that the time taken to reach the end points was longer in group B/D than in group D whether it was measured from the time of diagnosis or from the initiation of the first treatment (bromocriptine in group B/D or levodopa in group D). Conversely, the delay was similar in both groups when measured from levodopa introduction. The differences were mainly due to differences in the time taken for wearing off to begin.
Kaplan-Meier plots (fig 1) of the probability of not reaching the end point in group B/D and D differed widely as proved by the log rank test (X2 15-9, df= 1; p < 0-001). The Mantel-Haenszel estimation modified by Tarone indicated a relative risk of 1/4 21 = 0-24 in developing motor complications when bromocriptine was prescribed before levodopa.
Motor complications were not the only side effects during the study. Seven patients had psychiatric side effects (hallucinations or confusion) before the occurrence of motor end points: five in group B/D with 50 mg, 60 mg, 30 mg (plus 600 mg levodopa), 60 mg (plus 250 mg levodopa), and 40 mg (plus 400 mg levodopa) bromocriptine. Bromocriptine was withdrawn in three cases. The dose was decreased by 50% in the two other patients. In these five cases, the hallucinations disappeared and the follow up was continued until a motor end point was reached. Two patients of group D also had hallucinations with levodopa monotherapy before developing motor complications (350 and 400 mg/day). Levodopa was continued as it was not possible to reduce the dose because of the motor impairment. No neuroleptic treatment was prescribed. Clozapine was not available for this indication in France at this time. Figure 2 shows the mean doses of levodopa and bromocriptine at each six monthly visit. The daily dose of levodopa was significantly higher in group D than in group B/D from the 30th month of treatment. The mean doses of levodopa and bromocriptine in patients with or without motor complications were not different (data not shown).
There was no difference between the two groups in the severity of the disease assessed with the Hoehn and Yahr scale when the patients entered the study. At the end point or the last visit of follow up, the UPDRS motor scale showed no significant difference between the two groups (1 0 6 (1 1) in group B/D v 11 0 (1-5) in group "D").
Discussion
The study shows that motor complications (wearing off and peak dose dyskinesia) occurred later and were less numerous in the group treated with high doses of bromocriptine followed by levodopa than in patients treated with levodopa alone from the start. In Time (y) Figure 2 Mean (SEM) doses of bromocriptine and levodopa in the two groups ofpatients during the first six years of the study. The number ofpatients continuing the study is indicated in the bars for each period.
patients treated with levodopa, motor side effects were detected in 90% of the cases after three years of levodopa monotherapy. This is rapid compared with other studies.29-3' The difference is probably explained by the fact that we carefully and prospectively followed up our patients and thus often detected mild motor complications before they were noticed by the patients themselves. In contrast, motor complications occurred in 56% of the patients in group B/D. Nakanishi et al 32 described the occurrence of late motor side effects in 49% of patients treated with levodopa and 36% of B/D group. In their study, however, the dosage of bromocriptine was lower (mean value around 12-5 mg) than in the present work and no statistical evaluation was presented in their report.
The present trial also found that delaying levodopa with bromocriptine did not influence wearing off and peak dose dyskinesia in a similar way. In fact, the number of patients with wearing off was similar in groups B/D and D, but it occurred later when levodopa was given late (group B/D). Conversely, the frequency of dyskinesia was significantly lower in group B/D-that is, when levodopa was delayed. Our result is not in accordance with the data of Nakanishi et al'2 who described a similar frequency of dyskinesia in both groups (8-5% in B/D and 10% in D) after five years of treatment. They also found the same frequency of occurrence for on-off and wearing off phenomena in both groups.
The results of the present study suggest that wearing off phenomena and peak dose dyskinesias have different pathophysiological mechanisms. 29-3' Dyskinesia occurred significantly less often in the B/D group than in the D group. It has been shown that bromocriptine alone does not induce dyskinesia in previously untreated patients with Parkinson's disease61733 or in the primate MPTP model of parkinsonism. The incidence of dyskinesia is also reduced when bromocriptine or levodopa are given together early in the course of treatment.'2'3 This conclusion was recently discussed by Weiner's group.'4 5 The few patients in their study (10 in the levodopa group and seven in the early combination group) does not allow any definite conclusions to be reached. Our results show that the occurrence of dyskinesias was lower when the drugs were given together later. Several hypotheses can be proposed to explain this. It is possible that the more sustained dopaminergic stimulation elicited by bromocriptine reduces the occurrence of dyskinesia. It is also possible that the difference can be explained by the DI antagonist effect of bromocriptine or its inability to discriminate between the high and low affinity states of the D2 receptor. In our study, however, the symptomatic effect of bromocriptine allowed us to use lower doses of levodopa in the B/D group than in the D group. This difference may also explain our results as reducing the levodopa dose is the best way to reduce the intensity of dyskinesia.
Long term motor complications appeared after the same duration of treatment with levodopa in both groups. This suggests that the late motor complications encountered in patients with Parkinson's disease are indeed more closely related to the duration of the treatment with levodopa than to the evolution of the disease. Whether this difference can also be explained by the putative protective effect of the dopamine agonist as suggested by "in vitro studies"'5 remains a topic for future research. A recent multicentre study showing that bromocriptine reduced the risk of mortality in patients treated with levodopa (by more than 50%) has suggested a cardioprotective effect of bromocriptine.36 In our study, one patient in the B/D group and three in the D group died in October 1992. Our population is too small and our follow up too short to allow any conclusions on this point. We make two other comments about the present trial. Firstly, we prospectively followed two cohorts of previously untreated patients with Parkinson's disease who were randomly assigned to two different therapeutic regimens as soon as a dopaminergic treatment was considered necessary. By this means, most of the risk factors putatively influencing the occurrence of long term motor side effects were not significantly different between the two groups. The age at onset of disease was similar. The severity and the duration of the disease were similar when starting the treatment. The symptomatic improvement induced by both therapeutic strategies was similar at the end of the study. Therefore, we can assume that the differences in patient outcomes is mainly related to the difference in drug regimen. It is true, however, that the present study has a methodological limit because it was not blind. In fact, this trial must be considered as a long term pilot study as it was designed in the early 1980s when such a strategy had not been tested before. Since that time, blind studies built on similar patterns have been started with other dopamine agonists but have several years to run before their results become available.
Secondly, it is likely that a proportion of the patients enrolled in our study had extrapyramidal syndromes other than idiopathic Parkinson's disease. In fact, when reviewing the 60 cases in October 1992, two patients of the group B/D and two patients of the group D subsequently presented atypical features such as dementia, or pyramidal, dysautonomic, or cerebellar symptoms that make the diagnosis of idiopathic Parkinson's disease questionable. All of them, however, initially responded to dopaminergic drugs. The fact that we randomly allocated the treatments suggests that the same proportion of atypical Parkinson's disease should have been included in each arm of the study so that our results are still valid despite the methodological limits.
In conclusion, this study shows that a three year initial monotherapy with high doses of bromocriptine followed by a late use of levodopa as an adjunct delays the occurrence of long term motor complications usually found in patients with Parkinson's disease treated with levodopa alone from the beginning. Further studies must be performed to compare the results of this new strategy (late levodopa combination treatment with a dopamine agonist) with other therapeutic schemes. 
